SCHEMBL8234751

SCHEMBL8234751

CCc1csc(-c2ccccn2)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.63
KDM4E B2RXH2 9/20 0.51
RAB9A P51151 5/20 0.51
ALDH1A1 P00352 3/20 0.51
MAPT P10636 3/20 0.51
HSD17B10 Q99714 2/20 0.51
PKM P14618 1/20 0.51
GFER P55789 1/20 0.51
KDM4C Q9H3R0 1/20 0.51
CYP19A1 P11511 1/20 0.50
MAPK1 P28482 2/20 0.48
NPC1 O15118 3/20 0.46
ATM Q13315 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.44
TP53 P04637 2/20 0.44
TSHR P16473 1/20 0.44
ADORA1 P30542 2/20 0.43
ADORA2A P29274 1/20 0.43
LMNA P02545 3/20 0.42
CCR1 P32246 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8086835 0.83 PDE10A (0.58) PDE10AKDM4ERAB9AALDH1A1MAPT
SCHEMBL1893656 0.83 PDE10A (0.58) PDE10AKDM4ERAB9AALDH1A1MAPT
SCHEMBL1205231 0.83 PDE10A (0.55) PDE10AKDM4ERAB9AALDH1A1MAPT
SCHEMBL12862618 0.83 PDE10A (0.58) PDE10AKDM4ERAB9AALDH1A1MAPT
SCHEMBL6378638 0.81 PDE10A (0.55) PDE10AKDM4ERAB9AALDH1A1MAPT
SCHEMBL17503907 0.79 PDE10A (0.57) PDE10AKDM4ERAB9AALDH1A1MAPT
SCHEMBL19327449 0.78 LMNA (0.54) PDE10AKDM4ERAB9AALDH1A1MAPT
SCHEMBL27526928 0.78 PDE10A (0.53) PDE10AKDM4ERAB9AALDH1A1MAPT
SCHEMBL30606303 0.77 PDE10A (1.00) PDE10AKDM4ERAB9AALDH1A1MAPT
SCHEMBL6840490 0.77 PDE10A (1.00) PDE10AKDM4ERAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140194349-A1 HIV Protease Inhibiting Compounds ABBVIE INC. (US) 2014-07-10 US disclosed
US-8501786-B2 Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-08-06 US disclosed
US-20110028461-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME LLC 2011-02-03 US disclosed
US-7834043-B2 Prevent reproduct of aids virus ABBOTT LABORATORIES (US) 2010-11-16 US disclosed
US-20100249181-A1 HIV Protease Inhibiting Compounds ABBOTT LABORATORIES (US) 2010-09-30 US disclosed
US-7696226-B2 HIV protease inhibiting compounds ABBOTT LABORATORIES (US) 2010-04-13 US disclosed
US-20050159469-A1 HIV protease inhibiting compounds ABBVIE INC. 2005-07-21 US disclosed
US-20050148623-A1 Prevent reproduct of aids virus ABBVIE INC. 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148623-A1 Prevent reproduct of aids virus SERPINB1, PRSS1, SERPINA3 PDE10A 3164/4885KDM4E 2995/4885RAB9A 2076/4885
US-20050159469-A1 HIV protease inhibiting compounds SERPINB1, HPN, DNPEP PDE10A 2198/4885KDM4E 3048/4885RAB9A 2012/4885
US-20110028461-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 PDE10A 619/4885KDM4E 1825/4885RAB9A 1834/4885
US-20100249181-A1 HIV Protease Inhibiting Compounds SERPINB1, HPN, DNPEP PDE10A 2198/4885KDM4E 3048/4885RAB9A 2012/4885
US-20140194349-A1 HIV Protease Inhibiting Compounds SERPINB1, HPN, DNPEP PDE10A 2198/4885KDM4E 3048/4885RAB9A 2012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.